24,400 Shares in STAAR Surgical (NASDAQ:STAA) Purchased by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System purchased a new position in STAAR Surgical (NASDAQ:STAA) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 24,400 shares of the medical instruments supplier’s stock, valued at approximately $762,000.

A number of other large investors also recently bought and sold shares of STAA. SG Americas Securities LLC raised its holdings in shares of STAAR Surgical by 163.2% during the third quarter. SG Americas Securities LLC now owns 38,651 shares of the medical instruments supplier’s stock valued at $1,553,000 after acquiring an additional 23,965 shares during the last quarter. State of Alaska Department of Revenue raised its holdings in shares of STAAR Surgical by 403.9% during the third quarter. State of Alaska Department of Revenue now owns 30,197 shares of the medical instruments supplier’s stock valued at $1,213,000 after acquiring an additional 24,204 shares during the last quarter. Exchange Traded Concepts LLC raised its holdings in shares of STAAR Surgical by 14.0% during the third quarter. Exchange Traded Concepts LLC now owns 30,244 shares of the medical instruments supplier’s stock valued at $1,215,000 after acquiring an additional 3,716 shares during the last quarter. Defender Capital LLC. raised its holdings in shares of STAAR Surgical by 5.0% during the third quarter. Defender Capital LLC. now owns 543,397 shares of the medical instruments supplier’s stock valued at $21,834,000 after acquiring an additional 26,045 shares during the last quarter. Finally, Maryland State Retirement & Pension System acquired a new position in shares of STAAR Surgical during the third quarter valued at approximately $718,000. Institutional investors and hedge funds own 96.70% of the company’s stock.

Insiders Place Their Bets

In other news, Director Aimee S. Weisner acquired 1,750 shares of the company’s stock in a transaction dated Thursday, March 14th. The stock was acquired at an average cost of $38.11 per share, with a total value of $66,692.50. Following the completion of the purchase, the director now owns 10,864 shares of the company’s stock, valued at approximately $414,027.04. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 1.10% of the stock is owned by insiders.

STAAR Surgical Stock Up 0.1 %

STAA stock opened at $46.96 on Friday. The business has a fifty day moving average of $39.86 and a two-hundred day moving average of $35.68. The stock has a market cap of $2.31 billion, a price-to-earnings ratio of 109.21 and a beta of 0.86. STAAR Surgical has a 52-week low of $26.66 and a 52-week high of $73.13.

STAAR Surgical (NASDAQ:STAA) last posted its earnings results on Monday, February 26th. The medical instruments supplier reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.01). The business had revenue of $76.27 million for the quarter, compared to analyst estimates of $75.94 million. STAAR Surgical had a return on equity of 8.73% and a net margin of 6.62%. STAAR Surgical’s revenue was up 19.1% compared to the same quarter last year. During the same period last year, the business earned $0.04 EPS. As a group, sell-side analysts anticipate that STAAR Surgical will post 0.03 EPS for the current year.

Wall Street Analyst Weigh In

STAA has been the subject of a number of research analyst reports. Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a report on Thursday, April 4th. Piper Sandler cut their price target on STAAR Surgical from $40.00 to $33.00 and set a “neutral” rating for the company in a report on Tuesday, February 27th. William Blair raised STAAR Surgical from a “market perform” rating to an “outperform” rating in a report on Thursday, April 4th. Mizuho increased their price target on STAAR Surgical from $45.00 to $53.00 and gave the company a “buy” rating in a report on Thursday, April 11th. Finally, Canaccord Genuity Group increased their price target on STAAR Surgical from $32.00 to $46.00 and gave the company a “hold” rating in a report on Monday, April 8th. Seven analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $46.38.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.